Peripheral Neuropathy and cannabis in Pennsylvania
The state currently does not list this condition as qualifying, and the program does not provide open-ended physician discretion to add conditions. Verify with the state regulator, because programs change.
- ✗ No
- LEGAL
- 30-day supply as certif…
- POSSESSION
- $50/yr
- STATE FEE
- 7–21 d
- TIMELINE
Pennsylvania statute and program
The Pennsylvania Medical Marijuana Program is the operating authority for Pennsylvania patient certification. The authoritative legal text is: 35 P.S. §§ 10231.101 – 10231.2110: Medical Marijuana Act. The program portal is at Pennsylvania Medical Marijuana Program.
What the evidence says about cannabis and Peripheral Neuropathy
Peripheral neuropathy is damage to or dysfunction of the peripheral nervous system (nerves outside the brain and spinal cord). Common causes include diabetes mellitus, chemotherapy, HIV infection, alcohol use, autoimmune disease, vitamin deficiency, infection, trauma, and inherited disorders. Symptoms typically include burning or shooting pain, tingling, numbness, weakness, and loss of coordination, most often in a stocking-glove distribution affecting feet first and then hands.
For the full evidence base, including the NASEM tier, randomized trial summaries, and symptom-domain breakdown, read the mmjnow Peripheral Neuropathy page.
How to qualify in Pennsylvania
The Pennsylvania Medical Marijuana Program requires the following registration steps for a Peripheral Neuropathy patient (or any qualifying diagnosis):
- Register through the Pennsylvania Medical Marijuana Program patient portal. Pennsylvania requires the patient to register first, before seeing a practitioner. Patients create an account at the Department of Health Medical Marijuana Program online registry using their Pennsylvania driver license or state ID. The portal assigns a patient ID number that the patient then takes to a certifying practitioner.
- Get certified by a PA-registered practitioner. A Pennsylvania-licensed physician registered with the Medical Marijuana Program must evaluate the patient for one of the enumerated serious medical conditions under 35 P.S. §10231.103 (cancer, HIV/AIDS, ALS, Parkinson’s, MS, epilepsy, glaucoma, intractable seizures, IBD, neuropathies, Huntington’s, Crohn’s, PTSD, severe chronic pain, terminal illness, sickle cell, autism, anxiety disorders, Tourette’s, dyskinetic and spastic movement disorders). The practitioner issues an electronic certification.
- Pay the $50 state ID card fee. After certification appears in the patient’s portal account, the patient pays the $50 annual identification card fee online. The fee is reduced or waived for patients on Medicaid, PACE/PACENET, CHIP, SNAP, or WIC under PA Department of Health rules.
- Receive your card and purchase from a PA dispensary. Pennsylvania medical marijuana ID cards arrive by mail within roughly 7 to 14 business days. Patients may purchase up to a 90-day supply per visit (no flower restrictions since 2018) from any Pennsylvania licensed dispensary. Cards renew annually with a new practitioner certification.
- State registration fee
- $50
- Physician visit (typical)
- $150–$250
- Certification to card
- 7–21 days
- Out-of-state patients
- Not eligible
- Minors
- Eligible with caregiver
For full Pennsylvania registration steps, fees, and reciprocity rules, see the Pennsylvania cannabis-laws page.
ICD-10 code
A certifying physician documenting Peripheral Neuropathy for the Pennsylvania medical cannabis program will typically record ICD-10 G62.9 or SNOMED-CT 42658009 in the patient's record. The state registry does not itself collect ICD-10 codes in most programs, but the physician's chart is the audit trail if the certification is later reviewed.
Frequently asked questions
Does Pennsylvania list Peripheral Neuropathy as a qualifying condition for medical cannabis?
No. Pennsylvania's qualifying-condition list does not currently include Peripheral Neuropathy, and the state's program does not give physicians open-ended discretion to add conditions outside the list. Patients with Peripheral Neuropathy in Pennsylvania have limited in-state pathways under the medical program as written. Options to verify and pursue include: petitioning the state regulator to add the condition (where the statute permits public petitions); consulting a physician about whether a co-occurring listed condition could support certification; or reviewing whether the state's program is undergoing legislative expansion. Pennsylvania program rules change, so verify the current list with the regulator before drawing a final conclusion.
How do I get a Pennsylvania medical marijuana card for Peripheral Neuropathy?
Because Pennsylvania does not currently list Peripheral Neuropathy as a qualifying condition, a card for Peripheral Neuropathy alone may not be obtainable in-state under the program rules as written. Step one is finding a physician licensed in Pennsylvania who is registered with Pennsylvania Medical Marijuana Program and willing to evaluate Peripheral Neuropathy cases. Step two is collecting your records (diagnosis documentation, treatment history, and the ICD-10 code your physician will use) and bringing them to the certification visit. Step three is the physician's certification through the state registry, followed by the patient registration application, state fee, and waiting period before the card is issued. Pennsylvania does not honor out-of-state cards, so the certification process has to originate inside the state. The state minimum patient age is 18; minors generally require a parent or legal guardian to act as caregiver. The authoritative source for the current process is the Pennsylvania Medical Marijuana Program site at https://www.pa.gov/agencies/health/programs/medical-marijuana; the state updates fees, forms, and physician registration rules periodically.
What does the evidence say about cannabis for Peripheral Neuropathy?
For Peripheral Neuropathy, evidence is described as moderate (supportive controlled studies exist but the picture is mixed). The mmjnow condition page for Peripheral Neuropathy lays out the current evidence base, including the citations underlying that evidence tier — typically the National Academies of Sciences, Engineering, and Medicine consensus reports, federal agency guidance, and peer-reviewed reviews. Evidence quality is independent of state law: a state can list a condition for which evidence is limited, and a state can decline to list a condition for which evidence is strong. Patients deciding whether to pursue medical cannabis for Peripheral Neuropathy should review the underlying evidence (linked on the condition page) and discuss expected benefit, dosing, and risk with a clinician familiar with both Peripheral Neuropathy and cannabinoid pharmacology. Cannabis is not a substitute for evidence-based first-line treatments for Peripheral Neuropathy; the evidence position above describes whether trial data supports its use, not whether it should replace standard care.
Sources
- 35 P.S. §§ 10231.101 – 10231.2110: Medical Marijuana Actaccessed May 15, 2026
- PA Department of Health: Medical Marijuanaaccessed May 15, 2026
- NORML: Pennsylvania Lawsaccessed May 15, 2026
- 35 P.S. §780-113(a)(31): Possession penalties (PA Controlled Substance Act)accessed May 17, 2026
- 75 Pa.C.S. §1532(c): Driver license suspension on drug convictionaccessed May 17, 2026
- 75 Pa.C.S. §3802: Driving under the influence (DUI)accessed May 17, 2026
- Pennsylvania General Assembly bill search and trackeraccessed May 17, 2026
- City of Philadelphia Code §10-2102 (civil-citation ordinance, Bill 140377, 2014)accessed May 17, 2026
- City of Pittsburgh Code of Ordinances (Municode) — civil-citation ordinance 2015-1739accessed May 17, 2026
- City of Harrisburg Codified Ordinances (Municode) — Chapter 3-509, Ordinance 4-2014accessed May 17, 2026
- NASEM: The Health Effects of Cannabis and Cannabinoids (2017)accessed May 16, 2026
“Substantial evidence that cannabis is an effective treatment for chronic pain in adults.”
- NIH NINDS: Peripheral Neuropathyaccessed May 16, 2026